Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer

NCT04169997 is registered in ClinicalTrials.gov with Impact Therapeutics, Inc. as lead sponsor.

NCT NCT04169997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04169997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
Lead sponsor
Impact Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 24, 2019
Completion date
June 30, 2026
Enrollment
404 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer